Compare WLDN & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | TXG |
|---|---|---|
| Founded | 1964 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2006 | 2019 |
| Metric | WLDN | TXG |
|---|---|---|
| Price | $106.06 | $16.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 13 |
| Target Price | ★ $114.33 | $14.96 |
| AVG Volume (30 Days) | 203.7K | ★ 2.7M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.17 | N/A |
| EPS | ★ 2.79 | N/A |
| Revenue | ★ $651,926,000.00 | $641,814,000.00 |
| Revenue This Year | N/A | $4.50 |
| Revenue Next Year | $9.01 | N/A |
| P/E Ratio | $38.75 | ★ N/A |
| Revenue Growth | ★ 12.90 | 1.92 |
| 52 Week Low | $30.43 | $6.78 |
| 52 Week High | $121.00 | $20.34 |
| Indicator | WLDN | TXG |
|---|---|---|
| Relative Strength Index (RSI) | 62.47 | 46.37 |
| Support Level | $101.66 | $16.10 |
| Resistance Level | $105.88 | $18.38 |
| Average True Range (ATR) | 3.98 | 0.97 |
| MACD | 0.75 | -0.37 |
| Stochastic Oscillator | 76.45 | 3.18 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).